Form 4: Director Francis Duhay Sells enVVeno Medical Shares
Statement of Changes in Beneficial Ownership
Director Francis Duhay sold 140 shares of enVVeno Medical Corp common stock at an average price of $10.305 per share.
Summary
- Director Francis Duhay executed a sale of 140 shares of enVVeno Medical Corp (NVNO) common stock.
- The transaction occurred on June 11, 2026, at a price of $10.305 per share.
- Following this transaction, the reporting person maintains a direct beneficial ownership of 2,362 shares.
- The sale was conducted pursuant to a Rule 10b5-1 trading plan established in June 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-existing, automated trading plan and involved a relatively small number of shares.
Positives
- The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information or sudden changes in sentiment.
Negatives
- The sale represents a reduction in the director's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term stock sentiment.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling under pre-established 10b5-1 plans is a standard corporate governance practice and typically does not signal a change in the company's fundamental outlook or strategic direction.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is a standard industry practice for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.
Stakeholder Impact
- Minimal impact expected on shareholders given the small volume of shares sold and the pre-planned nature of the transaction.
Next Steps
- Continued monitoring of future Form 4 filings for further insider activity.
Key Dates
| Date | Description |
|---|---|
| 06/2025 | Adoption of the Rule 10b5-1 trading plan. |
| 06/11/2026 | Date of the reported stock sale transaction. |
| 06/12/2026 | Date of filing the Form 4. |
Keywords
enVVeno Medical, NVNO, Form 4, Insider Trading, Francis Duhay, Director Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.